deltatrials
Terminated PHASE4 INTERVENTIONAL 2-arm NCT02974686

Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation

Sponsor: Novartis Pharmaceuticals

Conditions Gastrointestinal Disorder, Functional Kidney Transplant Rejection
Interventions Everolimus Mycophenolic Acid
Updated 13 times since 2017 Last updated: Aug 7, 2020 Started: Nov 30, 2016 Primary completion: Sep 30, 2019 Completion: Sep 30, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

low recruitment

Other terminated trials from Novartis Pharmaceuticals

See all terminations from Novartis Pharmaceuticals

This PHASE4 trial investigates Gastrointestinal Disorder, Functional and Kidney Transplant Rejection and is currently terminated or withdrawn. Novartis Pharmaceuticals leads this study, which shows 13 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Aug 2019 · 14 months · monthly snapshot~Aug 2019 – ~Feb 2020 · 6 months · monthly snapshot~Feb 2020 – ~Sep 2020 · 7 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  4. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE4

  5. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE4

▶ Show 8 earlier versions

  1. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE4

  2. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE4

  3. Sep 2020 — Jan 2021 [monthly]

    Terminated PHASE4

  4. Feb 2020 — Sep 2020 [monthly]

    Terminated PHASE4

    Status: Recruiting → Terminated

  5. Aug 2019 — Feb 2020 [monthly]

    Recruiting PHASE4

  6. Jun 2018 — Aug 2019 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  7. Feb 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE4

  8. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
  • Washington University School of Medicine
Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations